Eliciting protective neutralizing antibodies (NAbs) against HIV-1 is daunting because of the extensive genetic and antigenic diversity of HIV-1. Moreover, broad and potent responses are uncommon even during persistent infection, with only a subset of adults developing broadly neutralizing antibodies (bNAbs) that recognize viral variants from different HIV-1 clades [1] [2] [3] [4] [5] [6] [7] [8] . It is not known whether bNAbs can also arise in HIV-1-infected infants, who typically progress to disease faster than adults 9 , presumably in part due to an immature immune system 10 . Here, we show that bNAbs develop at least as commonly in infants as in adults. Cross-clade NAb responses were detected in 20/28 infected infants, in some cases within 1 year of infection. Among infants with breadth of responses within the top quartile, neutralization of tier 2 or 3 variants from multiple clades was detected at 20 months after infection. These findings suggest that, even in early life, there is sufficient B cell functionality to mount bNAbs against HIV-1. Additionally, the relatively early appearance of bNAbs in infants may provide a unique setting for understanding the pathways of B cell maturation leading to bNAbs.
HIV-1-specific NAb breadth, which develops after several years of infection in some adults [1] [2] [3] [4] [5] [6] [7] [8] , has not been measured in infants. We assessed NAb breadth in 28 infants who acquired clade A, C and/or D viruses in utero, during delivery or through breastfeeding (median time of first HIV-1 detection = 1.5 months, range = 0-9.1 months) in the Nairobi Breastfeeding Trial 11 and who had plasma samples available after at least 12 months of life. Samples at the last time point after birth (median = 24 months, range = 12-30 months) were first screened against eight viruses representing clades A-D ( Fig. 1a) . Overall, 20/28 (71%) infants neutralized a tier 2 virus 12,13 from a different clade than the infecting virus (cross-clade responses) at a median time of 22.2 months after detection of infection (p.i.) (range = 11.4-28.2 months p.i.). Remarkably, four infants (BB539, BH026, BE012 and BL846) already had evidence of cross-clade responses by 11-15 months p.i., but we did not have samples to assess whether they ultimately developed more broad and potent NAbs at later time points.
On the basis of this initial screen, we tested the seven plasma samples (of the initial 28) that neutralized tier 2 viruses from all four clades against 15 other viruses representing various neutralization sensitivities 12, 14, 15 (Fig. 1b) . All seven plasma samples neutralized two or more viruses from each of four clades at a median time of 20.3 months p.i. (range = 12-28.2 months p.i.). BB391 and BG505 had the most impressive responses, neutralizing 91-96% of viruses. Purified IgG from these two infants neutralized HIV-1 variants, but not simian immunodeficiency virus (SIV) (Supplementary Table 1 ), confirming that IgG mediated their HIV-1-specific NAb breadth. Notably, BT326 and BG376 had cross-clade breadth against tier 2 and tier 3 viruses as early as 12-18 months p.i.
To confirm that bNAbs arose from de novo responses generated by infants in response to infection and to determine the kinetics of NAb breadth, we tested longitudinal samples, beginning at the earliest time point after birth ( Fig. 2 and Supplementary Fig. 1 ). For some infants tested at birth (BT326, BG376 and BF520), we observed high titers of NAb against a few viruses that were probably due to passively transferred maternal NAbs, as they waned by ~3 months, consistent with the kinetics of passive HIV-1 NAb decay 16, 17 . These titers rebounded and peaked at the last available time point, reflecting the development of de novo responses. For all infants, there was evidence of de novo responses at ~12 months p.i. that increased in potency over time (geometric mean half-maximum inhibitory concentration (IC 50 ) = 201-570 at the last time point). Of note, by 12 months of life (~8-12 months p.i.), BT326 and BN469 already had broad de novo responses, defined by neutralization of one virus or more across four clades with IC 50 > 100 (ref. 4), whereas BG376 and BF520 developed similar breadth by 18 and 15 months of life (12 and 11.2 months p.i., respectively; Supplementary Fig. 1) . These results confirm that de novo responses mediated NAb breadth and suggest that bNAbs can develop within the first year of life and HIV-1 infection.
We compared NAb breadth of the top two infants with bNAbs to that of adults by testing against six viruses ( Supplementary Fig. 2 ) used to identify HIV-1-infected adults with the top 1% of bNAb responses ('elite neutralizers') 4 . BB391 and BG505 had scores of 2.1, which fall short of the rare subset of adults with elite bNAbs (score ≥ 2.5) 4 . Nevertheless, by <2.5 years of HIV-1 infection, these infants had scores similar to those of the top 3 of 463 (0.7%) adult samples initially screened for bNAbs at ≥3 years p.i. in the prior study 4 and to those of QB850 and QA255 (neutralization scores of 2.3 and l e t t e r s 6 5 6 VOLUME 20 | NUMBER 6 | JUNE 2014 nature medicine 1.6, respectively), two adults with the broadest responses at ~5 years p.i. in previous screens of 48 and 70 women, respectively 5, 13 . Thus, bNAbs in these two children at ~2.5 years p.i. are approaching those found in the top 1% of adults identified from larger screens at later times p.i.
To determine whether infant NAb responses correlated with passive NAbs from the mother, we tested plasma from the first week of life. Although there was no correlation between passive and de novo NAb titers overall (Pearson's r = 0.29, P = 0.19), excluding BG505, an outlier in this analysis, resulted in a significant correlation between passive . 3c ) NAbs against tier 2 viruses from two or more different clades ( Fig. 1a) . Including BG505 in the analysis for the former group resulted in a weaker correlation (Pearson's r = 0.58, P = 0.06). These results suggest that antigenic features in the shared maternal-infant virus population may shape infant NAbs, but there may be unique factors contributing to de novo breadth in BG505.
Indeed, there was no correlation between infant de novo responses for the subset of seven infants with the greatest NAb breadth, either with passive NAbs from the infant's first week of life or with maternal NAbs prior to transmission ( Supplementary Fig. 3a,b) . These findings could suggest that viral determinants are not the only factor driving infant NAb breadth, although larger studies are needed to clarify this possibility. Next, we analyzed factors associated with de novo NAb breadth, including set-point viral load (SVL) 2,5 , duration of HIV-1 infection 1 , total and envelope (Env)-specific IgG levels 1 at the latest time point, and passive NAbs. We used a clade A Env that was previously shown to have highly exposed NAb epitopes 18 to assess IgG binding. In univariate analyses, SVL and Env-specific IgG levels were significantly associated with NAb breadth (P = 0.002 and P = 0.0004, respectively, Supplementary Table 2) , and this association persisted in multivariate analysis (P = 0.02 and P = 0.001, respectively, Supplementary Table 2 ). Moreover, SVL was significantly higher among infants with bNAbs identified in Figure 1 compared to those without bNAbs (P = 0.0004, Fig. 4a) , and there was a trend toward higher Env-specific IgG levels in the former compared to the latter group (P = 0.05, Fig. 4b) .
Currently identified bNAbs target four main epitopes on Env: glycan-dependent sites in V1-V2 (ref. 19) or V3 (ref. 20) , the CD4binding site (CD4bs) 21 and the membrane-proximal external region (MPER) 22 . Using experimental methods that are currently standard for detecting these bNAbs 2,3,19-22 , we found no evidence for NAbs with these specificities in the seven infant samples with NAb breadth, except for a modest anti-MPER response for BG505 ( Supplementary  Fig. 4) . This was true using mutations in different viral Envs (data not shown). Similarly, by using a computational algorithm to delineate polyclonal specificities 23 , we did not detect a consistent signal for a single dominant response against known epitopes (L.G., I. Georgiev, P. Kwong and J.O., unpublished data). However, the precision of the predictions may have been affected by the limited plasma availability, which necessitated the use of a reduced panel of only 13 viruses 23 . Overall, our experimental and computational mapping analyses suggest that infant NAb breadth may be mediated by a polyclonal response, a bNAb with previously undescribed specificity or both.
In summary, we have shown that HIV-1 bNAbs can develop early in life. Thus, despite having higher viral loads and faster disease progression compared to adults 7 , infants maintain sufficient B cell function to mount bNAb responses. Indeed, as seen in adults, higher SVL in infants was associated with bNAbs, supporting the hypothesis that early antigenic load drives NAb breadth 2,5,6 .
HIV-1-specific bNAbs isolated from adults after several years of infection display extensive somatic hypermutation [19] [20] [21] [22] . Infants can achieve adult-like IgG diversity and concentration by 8-12 and 12-24 months, respectively 10 , raising the possibility that rapid somatic hypermutation early in life may contribute to the development of infant bNAbs. The predominance of IgG1 and IgG3 over IgG2 in infants 10 may also enhance HIV-1-neutralizing activity [24] [25] [26] . Although HIV-1-specific passive IgG reduced viremia and accelerated NAb development in newborn macaques 27 , presumably by mitigating HIV-1-induced B cell dysfunction 28 , we found a trend toward a positive correlation between higher passive NAbs and infant SVL (data not shown), which, in turn, was associated with de novo breadth. Because only passive IgG matched to the infecting virus successfully reduced viremia in the prior study 27 , the failure of passive NAbs to control viremia in infants could be explained by the transmission of NAb escape variants 16 . Notably, an immunogen based on monomeric HIV-1 Env of the transmitted BG505 escape variant 16 elicited NAbs against tier 2 viruses in rabbits 29 , and the trimeric HIV-1 BG505 Env 30 , modified to increase stability, expressed epitopes for bNAbs 31, 32 . It is possible that the process of NAb escape from maternal and perhaps early de novo antibodies of vertically transmitted viruses Figure 3 Association between passive and de novo NAbs. (a) Correlation between passive and de novo infant average log 2 (IC 50 ) values. Samples were available for 22/28 infants. (b) Correlation between passive and de novo log 2 (IC 50 ) for infants with NAbs against tier 2 viruses from at least two different clades identified in Figure 1a and with plasma sample available within the first week of life (n = 11). (c) Correlation between passive and de novo log 2 (IC 50 ) for infants without NAbs against tier 2 viruses from at least two different clades identified in Figure 1a and with plasma sample available within the first week of life (n = 11). For all panels, infant de novo IC 50 values were obtained from the last available time point (the plasma sample used in Fig. 1) , whereas passive IC 50 values were obtained within the first week of life. For a and b, red dot represents data point for BG505. Pearson's r, 95% confidence intervals and P values shown in black and gray indicate analysis excluding and including BG505, respectively. Figure 4 Comparison of set-point viral load and Env-specific IgG for infants with and without bNAbs. (a,b) Unpaired t-test with Welch's correction comparing set-point viral load of infants with (n = 6, excluding BB391, who had no SVL measurement) and without (n = 21) bNAbs (a) and Env-specific (Q461.d1 gp120) log-transformed endpoint titers (EPT) of plasma from infants with (n = 7) and without (n = 21) bNAbs identified in Figure 1 (b) . Horizontal lines in a and b represent mean and 95% confidence intervals. npg indirectly exposed conserved epitopes that induced bNAbs, as shown in heterosexual infection 33 .
As infants are monitored frequently for infection in efforts to prevent mother-to-child transmission, pre-infection and longitudinal samples are available in many cohort studies. Given the growing interest in the field to delineate pathways to HIV-1-specific bNAbs, these samples may be especially valuable, as some infants appear to develop bNAbs relatively rapidly and at their early age may have been exposed to fewer non-HIV-specific antigens than their adult counterparts.
METHods
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ACkNOwLedGmeNts
We are grateful to the participants and staff of the Nairobi Breastfeeding Trial; P. Poignard (International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute) for providing envelope plasmids used for viruses in Supplementary Figure 2 We screened infants for bNAbs in this study if they had plasma samples available at least after 12 months of birth in order to increase our chances of detecting de novo antibodies. Twenty-eight infants met this criterion, of which 17 were breastfed and 11 formula-fed. Infants were defined as HIV-1 infected by PCR using peripheral blood mononuclear cells or dried-blood-spot DNA, and by HIV-1 RNA testing using the Gen-Probe HIV-1 Viral Load assay 11 . Time post-infection is defined as the time from the infant's first HIV-1-positive nucleic acid test.
For each of the 28 infants, we measured the presence of bNAbs at the last available plasma sample. To determine the kinetics of NAb breadth in 7 infants with the greatest breadth at the latest time point, we tested earlier available samples, beginning at either the first week of life (5 infants), month 3.7 (1 infant) or month 6 (1 infant). Maternal plasma samples were obtained from the last HIV-1-negative time point for their corresponding infants, or the earliest time point if the infant was predicted to be infected in utero. HIV-1 clade was determined by a combination of heteroduplex mobility assay of V1-C3 (21/28 subjects), and sequence analysis of V1-V5 (7/28 subjects) of maternal virus envelopes, as described previously 34 . Viral loads were quantified by the Gen-Probe HIV-1 viral load assay 11 . We also screened plasma samples from 2 HIV-1-infected adult women, QB850 and QA255, who were participants of a heterosexual transmission cohort in Mombasa, Kenya, for HIV-1-specific NAbs using samples from ~5 years p.i. QB850 is a top broad neutralizer identified in a screen of 12 superinfected and 36 singly infected women 13 , whereas QA255 is a top broad neutralizer in a similar screen of 70 singly infected women 5 .
Pseudovirus panels and neutralization assay. The 8-virus panel used in the initial screen for bNAbs includes 2 tier 1 and 6 tier 2 viruses representing clades A (Q461.D1, Q842.d16), B (SF162, TRO.11), C (QC406.F3, DU156.12) and D (QD435.A4, QB857.B3). Tier designation was taken directly from Seaman et al. 12 when available; for other viruses, tier designation was defined by comparing IC 50 values against pooled plasma 13, 17 to envelope variants of known tier designation based on Seaman et al. 12 . Viruses were obtained from infected Kenyans and were representative of major circulating subtypes, which are relevant to the infant cohort examined here. These viruses have been used to screen prior Kenyan cohorts 13, 15, 17 , and detailed virus characteristics have been described elsewhere 15 . Infant plasma samples that could neutralize a tier 2 virus from all 4 clades at an IC 50 >100 were classified as having bNAbs and were further screened against an additional 15 viruses, including 6 clade A (Q23.17, Q769.B9, Q259d2.26, BJ613.E1, Q168.a2, Q842.d12), 1 clade A/D (BF535.A1), 4 clade B (THRO4156.18, CAAN.A2, TRJO4156.18, PVO.4) and 4 clade C (ZM109F.PB4, DU422.1, DU172.17, CAP210.E8) viruses. We tested longitudinal infant samples and maternal pretransmission samples against 2 viruses each from clades A, B, C and D (Q461.D1, Q769.B9, SF162, TRO.11, QC406.F3, DU156.12, QD435.A4, QB857.B3). A negative control pseudovirus from the envelope of simian immunodeficiency virus (SIV), SIVMneCl8, was also tested against all plasma samples to confirm that neutralizing activity was HIV-1 specific. Plasma samples from BB391 and BG505, the top 2 broad neutralizers, were tested against a 6-virus panel that was previously used to identify elite neutralizers 4 . This panel consists of 1 clade A (94UG103), 2 clade B (JRCSF, 92BR020), 2 clade C (IAVI C22, 93IN905) and 1 clade CRF01_A3 (92TH021) virus.
To generate pseudoviruses, envelope plasmids were co-transfected with Q23∆env, an envelope-deficient proviral plasmid, as previously described 16 . Neutralization assays were performed using TZM-bl cells as previously described 16 . Heat-inactivated plasma samples (56 °C, 1 h) were tested using six twofold serial dilutions, starting at 1:100. IC 50 values represent the reciprocal plasma dilution resulting in a 50% reduction of virus infectivity 16 . For viruses not neutralized at the lowest dilution tested (1:100), IC 50 values of 100 were assigned for analyses. For viruses that did not reach 50% neutralization at the highest dilution tested (1:3,200) , IC 50 values of 3,200 were assigned for analyses. IC 50 values represent the average of at least 2 independent experiments.
Neutralization scores. For BB391 and BG505, the top 2 broad infant samples, and QB850 and QA255, the top 2 broad adult samples in a Kenyan heterosexual transmission cohort 5, 13 , we calculated a 'neutralization score' using a scoring procedure that was deemed most suitable for identifying samples with bNAbs ('Score 1'), as described in Simek et al. 4 . Briefly, an individual's neutralization score is the average of log-transformed titers against 6 viruses in Supplementary Figure 2 . We obtained log-transformed titers by dividing IC 50 values by 100 followed by a log 2 transformation and adding 1: (Y = log 2 (IC 50 /100) + 1). All IC 50 values below the limit of detection of 100 were assigned a log-transformed titer of 0 for calculating neutralization scores.
IgG purification and quantification. We purified total IgG from 50 µl of plasma using the Melon Gel IgG purification kit (Thermo Scientific) in a final volume of 500 µl (1:10 dilution in purification buffer). Purified IgG was quantified and tested in neutralization assays at a starting concentration of 2 mg ml −1 for BG505 or 1 mg ml −1 for BB391, who had more limited sample, against Q461.D1, Q842.d16, TRO.11, QC406.F3, QD435.A4, and SIV.
Total and HIV-1-specific ELISA. Total IgG ELISA in plasma samples from mother-infant pairs were quantified using a human IgG ELISA kit (Immunology Consultants Laboratory) according to the manufacturer's instructions. We performed HIV-1 envelope-specific IgG ELISAs as previously described 1 , using 25 ng/well of purified recombinant gp120 (Immune Technology Corp, New York, NY) from Q461.D1, a tier 1B clade A variant with optimal exposure of multiple epitopes 18 . Plasma samples were serially diluted twofold starting at a dilution of either 1:1,000 or 1:10,000 to obtain an endpoint titer (EPT), defined as the reciprocal dilution at which the average optical density (OD) value was greater than or equal to twice the average OD value of background. Total IgG levels and EPT values used in analyses were the average of at least 2 independent experiments.
Expression and purification of RSC3 proteins. Proteins were expressed and purified as described by Wu et al. 21 , with slight modifications. Briefly, proteins were produced by transient transfection of 293F cells (1.2 × 10 6 in 400 ml) using 293fectin (Invitrogen). Culture supernatants were harvested 5 days after transfection, filtered through a 0.45-µm filter, and concentrated by centrifugation in 100-kDa Centricon-Plus 70 filter tubes (Millipore) with buffer exchange into PBS. Proteins were first purified by DEAE sepharose (GE) ion exchange chromatography, followed by His-Select Nickel (Sigma) affinity chromatography.
Epitope mapping. To screen for PG9/16-and PGT128-like 19, 20 NAbs, we compared neutralization of a commonly used clade A wild-type virus, Q23. 17 (refs. 2,33) , to that of N160K or N332A mutants, respectively, in most infant plasma samples. Mutants were generated by overlap PCR and verified by sequencing. BG376 and BN469 could not neutralize Q23.17 at the lowest dilution tested (1:100) and were instead screened against JRCSF and corresponding mutants, which have been used to detect PG-and PGT-like antibodies in previous studies 19, 20 . Results were confirmed using a tier 1B clade A virus, Q461.D1, and its corresponding N160K mutant (data not shown). The effect of N332A could not be confirmed in Q461.D1 as this virus lacks N332. Thus, in the case of BG505, who had notably broad responses, we confirmed mapping results with the N332A mutant in the context of JRCSF (data not shown). In all experiments, PG9 and PGT128 were included as positive controls for N160K and N332A, respectively, whereas VRC01 21 , which targets the CD4 binding site, served as a control for nonspecific effects of both mutants. We assessed for the presence of CD4bs (VRC01-like) antibodies by ELISA as described above for Q461.D1 gp120, except a resurfaced stabilized core (RSC3) gp120 protein and its mutant (RSC3∆371I) were used 21 , and plasma samples were tested at a starting dilution of 1:100. EPT was calculated npg as described above. To map MPER specificities, we compared neutralization of a HIV-2 full-length construct (7312A) to that of a HIV-2/HIV-1 MPER chimera (7312-C1) 22 .
To assess NAb specificity using the computational method described by Georgiev et al. 23 , IC 50 values were obtained for the following 13 viruses: CAAN.A2, CAP210.E8, DU156.12, DU172.17, DU422.01, PVO.04, Q168.a2, Q23.17, Q842.d12, THRO4156.18, TRJO4551.58, TRO.11 and ZM109.PB4. This panel represents the minimal virus collection validated by this method, although the antibody classification accuracy may be sensitive to the size of the virus panel 23 .
Statistical analyses. All analyses were performed in R 2.10.1 and GraphPad Prism 9.0. Infant de novo antibodies were assessed at the latest available time point for all analyses. Average log 2 (IC 50 ) values used for analyses were based on neutralization of 6 tier 2 and 2 tier 1 viruses, including 2 clade A (Q461.D1, Q769.B9), 2 clade B (SF162, TRO.11), 2 clade C (QC406.F3, DU156.12) and 2 clade D (QD435.A4, QB857.B3) viruses.
For a subset of 22 infants who had plasma availability within the first week of life, we determined the association between passive and de novo antibodies. IC 50 values for passive neutralization for 13/22 infants were available from a previous study investigating the breadth of passive NAb responses 17 starting at a plasma dilution of 1:25, whereas neutralization data for the remaining 9/22 infants were generated in this study at a starting plasma dilution of 1:100 to preserve sample. For all analyses, viruses not neutralized at the lowest plasma dilution tested were assigned IC 50 values of 25 or 100 (the lowest dilution tested in the prior or current study, respectively). We used Pearson's correlation coefficient to compare the average log 2 (IC 50 ) values of passive and de novo antibodies, as well as maternal and de novo antibodies.
Set-point viral load measurements, defined as the first available measurement within 4-12 months of infection 9 , were available for all infants except BB391. To compare set-point viral loads (log 10 copies ml −1 ) and Env-specific IgG log 2 end-point titers (EPT) between infants who developed bNAbs (n = 7) and those who did not (n = 21), as determined in Figure 1 , we performed unpaired t-tests with Welch's correction. Univariate linear regression models were used to identify factors associated with de novo NAb breadth, defined as the average log 2 (IC 50 ) value against 8 viruses described above. In these models, logarithmic transformations were performed for passive NAb IC 50 values against these viruses, set-point viral load and Env-specific IgG EPT. Duration of HIV-1 infection was calculated by subtracting the time point of the first HIV-1-positive result from the plasma time point used for neutralization assays. For infants who were predicted to be infected in utero based on an HIV-1-positive cord blood sample, or at delivery, the time point of first HIV-1 positive result was set to 0. Covariates significantly associated with de novo NAb breadth in univariate analyses (P < 0.05) were included in multivariate models. Analyses involving passive NAbs and set-point viral load were performed for 22/28 and 27/28 infants, respectively. No statistical method was used to predetermine sample size. The experiments were not randomized.
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